Price drops means more cancer drugs routinely available to patients, says NICE

2 March 2017

The National Institute for Health and Care Excellence (NICE) says it is now at the half-way point of its requested review of drugs, approved and still available only through the old Cancer Drugs Fund (CDF).

In all cases so far where the cost-effectiveness watchdog for England and Wales has been able to make recommendations for routine National Health Service (NHS) use, companies have reviewed and reduced their prices, and in some cases provided clearer evidence.

The NICE is appraising 24 drugs, across 33 cancer indications that have been supplied to patients who applied for conditional funding through the CDF.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK